Vaxess Technologies Awarded Grant for Development of the MIMIX-Flu Broadly Protective Influenza Vaccine

Share Article

NIH fast-track SBIR grant will drive the MIMIX smart release patch towards a phase I clinical trial

Vaxess Technologies, Inc., an innovative biotechnology company developing the MIMIX smart release patch was awarded a fast-track Small Business Innovation Research Grant (SBIR) from the National Institute of Allergy and Infectious Diseases, (NIAID grant number 1R44AI142948 - 01A1) part of the U.S. National Institutes of Health (NIH). Vaxess will receive up to a total of approximately $2.2 million over the course of the award if project milestones are met.

Nearly 20 percent of the global population is infected by influenza viruses every year, leading to severe illness and hospitalization for millions of individuals. Despite the availability of influenza vaccines, their public health impact is limited due to suboptimal efficacy and challenges with patient compliance.

Vaxess is developing a broadly protective influenza vaccine using the MIMIX smart release patch technology. This approach has demonstrated the capacity to enhance efficacy of commercially available, FDA-approved influenza vaccines, as well as ease distribution and administration to patients. The MIMIX smart release patch enhances responses against both vaccine-included and drifted influenza strains through the use of sustained antigen presentation, more accurately mimicking a natural infection thereby driving stronger, broader, and more durable HAI titers and influenza-specific T-cell responses. Moreover, immunization via the shelf-stable MIMIX smart release patch can simplify delivery and patient administration.

“We are grateful for the support of the NIH in advancing towards clinical development of a technology that has the potential to address one of the most pressing national and global health priorities,” said Vaxess Vice President of Policy and Strategy, Livio Valenti. “The MIMIX smart release patch has demonstrated to increase existing flu vaccine efficacy and advancing toward the creation of a universal flu vaccine quickly. Moreover, the patch does not require refrigeration, is painless, and can be easily administered at home; additional benefits that will increase immunization rates here in the US and globally.”

About Vaxess Technologies

Vaxess Technologies is developing the MIMIX smart release patch, the easiest and most effective way to deliver medicines and vaccines. The patch releases treatments at their most beneficial duration, after just one short and painless application. The controlled release of the MIMIX patch simulates the pace of a natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response, ultimately boosting a vaccine’s effectiveness. Engineered for stability, the MIMIX patch does not require refrigeration and can be ordered, shipped, and applied at home, all without a visit to the doctor. The MIMIX patch is virtually painless and applied like an adhesive bandage. After the prescribed wear time is up, it’s removed and thrown away while the medication continues to be delivered.

For more information please visit the company website at http://www.vaxess.com or send additional inquiries to contact(at)vaxess.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Livio Valenti
@Vaxess
Follow >
Vaxess Technologies
Like >
Visit website